At abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.

Alamar Biosciences is unlocking the power of fluid biomarkers with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Platform utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains ~250 important markers related to immune and inflammatory diseases and will run on our ARGO™ HT System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

Almac Diagnostic Services Always a move ahead in precision medicine Your global partner for biomarker discovery, development & commercialisation. Our global CLIA and CAP accredited laboratories cover UK, Europe, USA and APAC regions. Our cores services include: • Genomic Services • Clinical Trial Assays • Companion Diagnostics Make the winning move today

ARC Regulatory is a niche consultancy, offering global regulatory and clinical research solutions for first in human studies. ARC also offers a full CRO service to the precision medicine and in vitro diagnostic medical device industry. ARC’s mission is simple. From its headquarters in Belfast, Northern Ireland, it actively supports companies from the world’s big pharma players to diagnostic firms and novel start-ups, in the search to find kinder patient treatments. By guiding customers through the complex, myriad of international regulatory and research requirements, ARC facilitates comprehensive, global market access for new medical discoveries. ARC is proud to be a trusted partner in the global ambition to improve patient care, leveraging its team’s expertise in delivering high quality, accelerated clinical research for biomarker diagnostics. Learn more at www.arc-regulatory.com

Aspect Analytics develops enterprise software to analyze and integrate spatial omics data. Spatial technologies are steadily maturing into a key enabler in drug development, biomarker discovery, and life science research. With spatial omics datasets commonly generating tens to hundreds of gigabytes of complex data in a single experiment, data analysis is becoming a critical bottleneck in the adoption of this emerging technology. Aspect Analytics bridges the gap between algorithmic development in bioinformatics research and enterprise-grade software platforms to support key spatial omics-based applications. Our software can (i) extract maximal knowledge from spatial data, including co-registration with different modalities, (ii) scale up for high-throughput applications and (iii) provide integrated data management, traceability and more. Aspect Analytics enables breakthrough research and facilitates cross-disciplinary teamwork by bringing spatial multi-omics data into a single view, collaborative platform.

Bio-Techne empowers researchers in Life Science and Clinical Diagnostics by providing high-quality reagents, instruments, custom manufacturing, and testing services. Our family of brands creates a unique portfolio of products and services.

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.

BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to life science and diagnostic industries. Recognized as an industry leader, we specialize in control and disease state samples including human and animal tissues or preparations, cell and gene therapy products, blood, and other biofluids, as well as ADME contract research services from standalone bioanalytical support through tiered in vitro studies with submission-ready reports to customized consulting. By combining our technical expertise, exceptional customer service, and unmatched access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.

BioLizard is your partner for all of your scientific data needs. From bioinformatics and data analytics to predictive analyses using AI/ML or software development - we support you in accessing vital, data-driven insights that drive your life sciences research forward. Our team of experienced bioengineers, data scientists, software engineers & IT experts combines extensive computer science expertise with deep biological knowledge. The name BioLizard originates from the fact that lizards are agile and able to adapt to new environments. Our expert ‘Lizards’ can support you no matter where you are in the world, and in a flexible, proactive, and agile way to drive your data-driven research forward.

Canopy Biosciences, a Bruker company, empowers innovation by providing access to cutting-edge spatial biology and multi-omic tools so biomedical researchers can drive scientific discovery faster. Our proprietary technology ChipCytometry™ is a quantitative multiplex immunofluorescence imaging method for the spatial analysis of complex tissues and mapping of cell populations with single-cell resolution. Supported by Canopy Spatial Services™ with our CLIA-certified laboratory, we provide a unique collection of spatial and single-cell technologies that accelerate the understanding of cellular diversity and interaction. Learn more at CanopyBiosciences.com.

Leading provider of specialized precision medicine laboratory services with integrated platforms in immunology, histopathology, proteomics, genomics, and related specimen collection and logistics services. CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials, and operates globally with laboratories in Canada, USA, Belgium, Australia, and China.

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Concept Life Sciences is a leading Contract Research Organization (CRO) specializing in chemistry, biology, ADME&DMPK, and toxicology services. Our focus spans key therapeutic areas, including neuroscience, oncology, immuno-oncology, and immunology. Committed to excellence, we offer tailored solutions to accelerate your research and drug development.

Diagnexia Clinical Trials stands at the forefront of revolutionising pathology services for clinical trials, addressing critical challenges with innovative solutions. Diagnexia’s integrated platform facilitates rapid pathology reviews, enhances collaborative research, and ensures seamless data integration. By bridging the expertise gap with a team of expert pathologists, Diagnexia accelerates the development of complex studies, emphasising speed, accuracy, and reliability. Diagnexia’s comprehensive service offerings span across key disease areas, making Diagnexia a pivotal partner in advancing clinical research with precision and expertise.

Diagenode, a Hologic Company, is a leading provider of epigenomics with more than 20 years of expertise in the field. Our service can help you advance biomarker discovery and validation by providing the powerful combination of epigenomics and bioinformatics. This new dimension of epigenomics can bring you novel insights that go beyond genomics for early detection, patient screening, MRD and much more. We partner with you to create a customized end-to-end service based on the best technology that will shorten timelines for translational research and biomarker validation prior to clinical trials.

Discovery Life Sciences is the company of Biospecimen and Biomarker Specialists, combining the world’s largest commercial biospecimen inventory and procurement network with preeminent multi-omic biomarker service laboratories, including genomic, tissue biomarker, proteomic, and cell-based services to accelerate new therapies supported by biomarker and companion diagnostic programs for cancer, infectious disease, and other rare and complex conditions.

Foundation Medicine, Inc. transforms cancer care by developing comprehensive genomic profiling assays to identify the molecular alterations in a patients cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.

Genseq provides best-in-class next-generation sequencing services to the biopharma and clinical research sectors worldwide. Operating from our CAP-accredited laboratory in Dublin, and equipped with state-of-the-art sequencing platforms, our highly experienced team consistently generates high quality multiomic data at scale to meet our customers’ diverse project goals. Genseq’s comprehensive range of laboratory services includes DNA sequencing, RNA sequencing, single cell sequencing, microarrays, bioinformatic analysis, biobanking and sample management. The data generated at Genseq has a broad range of applications ranging from biomarker identification to patient stratification for clinical trials. From sample receipt to data analysis, Genseq take care to maximise the potential of every sample, every time.

Indivumed Services, a Crown Bioscience Company, is a global contract research organization (CRO) that offers an industry-leading oncology biobank and a range of service platforms to advance oncology and immuno-oncology drug discovery and development. Holding a unique biobank of clinical specimens, unrivalled in quality and associated clinical history, which currently totals almost one million patient samples, the company partners with extensive clinical network of more than 60 entities in the United States, Europe, and Asia providing direct and controlled access to relevant surgical biospecimens and blood samples. Further known for their enhanced immunohistochemistry and spatial transcriptomics, Indivumed Services’ platforms complement a range of established Crown Bioscience capabilities supporting biomarker discovery. Indivumed Services is headquartered in Hamburg, Germany, with a US-based subsidiary in Frederick, Maryland, USA, and employs approximately 120 people across these sites. Find out more: www.indivumedservices.com

Inoviv is an LC-MS proteomics services company providing comprehensive end-to-end quantitative biomarker solutions to biotech, pharma, and academia for all stages of drug development: from experimental design and sample processing through method development, data acquisition, and analysis. With decades of experience validating discovery and targeted LC-MS proteomics workflows, our LC-MS assays demonstrate exceptional throughput and specificity fit for FDA/EMA regulatory submission. We offer both custom designed and pre-validated tailored IP-MS and LC-MS assays which are expertly curated to elucidate treatment efficacy, target engagement and MoA, quantify different proteoforms, and facilitate patient selection in a wide range of tissue and biofluid samples. Current solutions support work in neurodegeneration, oncology, fibrosis, cardiovascular disease, and beyond. Inoviv's strong internal molecular biology and bioinformatics expertise also allow the layering of multiple ‘omics datasets, providing valuable in-depth insights into disease biology and mechanism to inform decision making. Please visit our website at www.inoviv.com to schedule a meeting with our experts and learn more about how we can help accelerate your drug development goals.

Intertek Pharmaceutical Services – Bringing Quality & Safety to Life. With Intertek’s bioanalytical services, you gain a partner with extensive experience in biomarker assays, testing, and guidelines. Our biomarker assay services enable you to understand your drug's safety and efficacy. With over 25 years experience at our GxP facility in Manchester, we continue to support your pre-clinical and clinical trials, by developing and validating bespoke assays to suit your requirements. Complimentary to our technical expertise, we utlise an array of multiplexing platforms to support your studies, such as, ELISA, MSD, Gyros, Quanterix etc. Through close collaboration with our platform partners over the years, we remain at the forefront of the industry, by continuing to develope and validate a forever growing range of multiplex biomarkers for our clients. The innovative bioanalysis services provided by Intertek are delivered with precision, pace, and passion, so you, our customer, can go forward with confidence. Visit website https://www.intertek.com/pharmaceutical/immunochemistry/biomarker-assays/ Follow us on LinkedIn https://www.linkedin.com/showcase/intertek-pharma/

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.

Lunaphore Technologies S.A. – a Bio-Techne brand, is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.

Merck is a prominent supplier to the global Life Science industry and dedicates itself to providing the best possible immunoassays for research purposes. With our immunoassay solutions portfolio, you can use our industry-leading MILLIPLEX® multiplex panels to comprehensively survey multiple analytes using Luminex® xMAP® technology, or you can perform femtogram/mL biomarker analysis using our ultrasensitive SMCxPRO® immunoassay platform, and we have engineered our Conferma® ELISAs for endogenous detection and lot-to-lot consistency. We also offer a portfolio of >1,300 ELISAs and EIAs, covering a diverse range of species, research areas, and sample types. With our biomarker solutions, you can expect reliable measurements, a user-friendly experience, and expert scientific partners to help drive your biomarker projects. We continuously update our immunology, oncology, neuroscience, and veterinary medicine portfolios. In addition, our Custom Assay Development and Innovation (CADI) team comprises experienced scientists who will work with you to develop custom immunoassays for your biomarker(s) of interest, accelerating your projects from discovery to clinical trials and allowing you to focus on the next stage. Our Products are for research use only. Not for use in diagnostic procedures. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and high-quality insights that expand and accelerate the impact of life sciences research. With more than 20 years of experience, 10,000+ projects, 2,800+ publications, and ISO 9001:2015 and CLIA certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Leveraging the company’s market-leading platform and the world’s largest proprietary metabolomics reference library, Metabolon provides scalable, customizable metabolomics and lipidomics solutions delivering biomarker discoveries and innovative diagnostic tests to support customer needs from discovery through clinical trials and product life-cycle management.

NanoString, a Bruker company, is a leader in spatial biology offering an ecosystem of innovative discovery and translational research tools that empower scientists to map the universe of biology. The GeoMx® Digital Spatial Profiler is a flexible reliable solution, combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics. The CosMx™ Spatial Molecular Imager is a single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. For more information, please visit www.nanostring.com.

Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. Nordic Bioscience is engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.

Novigenix pioneers AI-driven healthcare solutions, analyzing RNA data to personalize cancer treatments and improve patient outcomes. Leveraging molecular technologies and AI, Novigenix maps immune system responses, facilitating tailored therapeutic advancements based on individual immune response profiles. For over a decade, Novigenix has demonstrated leadership in bringing precision immunology to the market, integrating multi-omics data with AI through its proprietary LITOSeek™ platform. This innovative approach offers insights into patient immune responses, driving precision therapy developments.

Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 100 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore’s technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture. Oxford Nanopore devices sequence DNA/RNA directly and sequence short to ultra-long fragments of DNA, for a truly comprehensive picture of the genome. Data is streamed in real-time and can enable rapid insights. The technology is fully scalable — from pocket-sized to ultra-high throughput devices. Small formats such as Flongle address the need for on-demand, rapid, smaller tests or experiments, and can be used in labs or in the field. The pocket-sized MinION is a powerful and portable sequencing device that can deliver high volumes of long read sequence data. The benchtop GridION Mk1 can run up to five MinION or Flongle Flow Cells at a time, on demand, for projects requiring larger sample numbers. PromethION is suited to high-yield, high-throughput projects, designed to offer on-demand use of up to 48 flow cells (depending on device) for use in core labs, academic institutes and for population-scale sequencing projects alike

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect MRD and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.

Precision for Medicine is the first global, precision-medicine, clinical research organization. Purpose-built to shift the development curve for life sciences clients, we incorporate laboratory expertise, new technologies, clinical trial excellence, comprehensive biospecimens solutions and advanced data sciences at every stage. Our integrated approach is designed to maximize insights into patient biology and to accelerate the pace of scientific discovery and approval. With 7 specialty labs and 3500+ professionals worldwide, we help accelerate life-changing treatments anywhere around the globe.

Propath UK is a specialist CRO providing GCP and GLP compliant research services in molecular pathology, spatial biology (NanoString GeoMx® and CosMx,™ the Lunaphore COMET™ and the Akoya PhenoCycler®-Fusion), image analysis, gene expression(NanoString nCounter® including TIS, LST, PAM50 single signature reporting) and histopathology. We have gained a significant depth of expertise and experience within these areas and built a reputation within the biopharmaceutical sector over 35 years, by providing a consistent and responsive service for thousands of pre-clinical and clinical studies. To learn more, please visit www.propath.co.uk

We are a leading multiplex proteomics company with over 20 years of experience. Harnessing the power of multi-platform proteomics, we combine the benefits of state-of-the-art technologies, including Olink & Luminex, to offer novel products and solutions for biomarker discovery, development and validation. Our GMP, ISO13485 and ISO9001 compliant quality management systems enable us to move beyond traditional CRO offerings and translate discovery ideas into IVD products.

Proteome Sciences is a CRO specialising in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterise proteins and their associated post translational modifications. By using LC-MS2, SysQuant® and TMTcalibratorTM methodologies we can detect up to 8,000 of proteins/sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment._x000D_ These key protein biomarkers can then be measured in a GCLP accredited Targeted Assay in a clinical trial, via a multiplexed assay of up to 100 proteins/sample._x000D_ New! We now offer Single Cell Proteome analysis._x000D_ New! We have just opened a full service lab in San Diego!

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,000 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.​ ​

As an established IVD company, Randox Biosciences is dedicated to advancing scientific discovery, drug development and diagnostics. Spanning four key divisions: Life Sciences, Pharma Sciences, Research and Molecular; Randox Biosciences offers complete tailored solutions for clinical and research use. From initial cultivation of raw materials for assay development, through to providing companion diagnostics, molecular and protein based custom assays across a range of therapeutic areas, we assist Pharma, Biotechs and CROs move away from a “one treatment fits all” approach. Our aim is to advance the future of personalised medicine approaches to enable a better understanding of the complexity and variability of disease and increase efficacy of treatment. Randox patented Biochip technology, has changed the landscape of diagnostic testing forever and has established Randox as a global leader. Biochip technology is a multiplex platform, providing an unrivalled increase in patient information per sample, meaning the patients need comes first.

Our global bioanalytics division has an extensive track record across therapeutic modalities and biological matrices, including conventional small molecules, peptides, large proteins and antibodies, antibody-drug conjugates, and oligonucleotides.

Rules-Based Medicine (RBM), a Q2 Solutions Company, is the world’s leading multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture®). RBM’s internally developed and manufactured immunoassays based on Multi-Analyte Profiling (MAP) and Single-Molecule Array (SimoaTM) ultrasensitive immunoassay technology provides translational and clinical researchers with reproducible and quantitative data for a few or hundreds of human proteins. The comprehensive menu provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments. RBM’s CLIA certified biomarker testing laboratory is located in Austin, TX. Q2 Solutions is a leading global clinical trial laboratory services organization providing bioanalytical, genomics, vaccines, flow cytometry, anatomic pathology, immunoassay, companion diagnostics and central laboratory services with secure, enterprise-wide biospecimen and consent management solutions. With our industry-leading science, partnership approach and innovative solutions, we’ll make sure our clients get the results that will turn patients’ hope into the help they need.

Sapient is a biomarker discovery organization providing bespoke services for metabolomics, lipidomics, and proteomics data generation and analysis, enabling biopharma sponsors to go beyond the genome to accelerate precision drug development. Using state-of-the-art, high-throughput mass spectrometry technologies, Sapient enables nontargeted multi-omics measurements to capture thousands of dynamic biomarkers in human, preclinical, and cellular biosamples, across thousands of samples at a time. These technologies are leveraged within a larger discovery infrastructure that includes a comprehensive biocomputational framework for analysis of large-scale, multi-omics data;robust quality control analysis;and mapping of key biomarker-phenotype associations. Sapient can cross-validate discoveries using our proprietary in-house longitudinal Human Biology Database that includes data from over 100,000 human biosamples with paired phenotypic measures. Together our approaches enable rapid identification, validation, and translation of dynamic biomarkers of biological processes, disease mechanisms, and drug response across all drug development phases.

Sengenics is a proteomics company that has developed unique protein folding technology, KREX®, used for high throughput biomarker discovery. Our technology supports precision medicine by providing physiologically relevant disease associated proteomics data to guide clinical research. Our platform allows for the discovery and validation of autoantibody biomarker signatures across diseases, enabling patient stratification, drug response prediction, and companion diagnostics development. Sengenics has collaborations with pharmaceutical companies and partnerships with industry groups including Personalized Medicine Coalition (PMC), Human Proteome Organization (HUPO) and Foundation for the National Institutes of Health (FNIH). Sengenics is an affiliate company of the Milner Therapeutics Institute.

Located in Utrecht, the Netherlands, our purpose-built single-cell sequencing lab is operated by a team of PhD-level scientists, some of whom have pioneered the single-cell platforms we employ to deliver exceptional service. At Single Cell Discoveries, we are dedicated to crafting customized solutions for your unique challenges, ensuring rapid turnaround times, and unlocking high-impact biological insights. We eat, sleep, and breathe single-cell biology so you can focus on advancing your discovery program

SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a 55 microliter plasma or serum sample, SomaLogic can run 11,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body. For more than 20 years SomaLogic has supported pharmaceutical companies, academic and contract research organizations who rely on protein detection and analysis technologies to fuel drug, disease, and treatment discoveries.

Through ultrasensitive InSituPlex® assays and advanced, AI-driven spatial analysis, Ultivue empowers scientists developing precision cancer therapies to generate quantitative, high confidence insights in just a fraction of the time.

Volition is a leading epigenetics biomarker company, renowned for its proprietary liquid biopsy immunoassay approach to profiling cell-free circulating nucleosomes. Nu.Q® Discover, a fee for service model, offers access to assays that provide Non-Invasive, Real-Time, Quantitative insights, adding significant value in preclinical and clinical drug development programs across multiple therapeutic areas, including oncology and inflammatory diseases. Nu.Q® Discover, encompasses a range of assays targeting biomarkers associated with innate immune activation (NETosis) and epigenetic inhibitors (HDACi, LSDi, EZH2i, EEDi, SWI/SNF complex and more..). Nu.Q® assays effectively correlate with disease and tumor burden, making them ideal for use as surrogate endpoint markers of treatment response, minimal residual disease, and relapse monitoring. Our development pipeline includes assay development, a novel proteomics approach to epigenetic profiling of circulating nucleosomes using Mass Spec, and Toxicity Monitoring assays. Join us at Biomarkers 2024 to explore how we our biomarkers can streamline your drug development efforts.